JNCCN 360 - Immunotherapy

Advertisement

Advertisement

Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Combining Checkpoint Inhibitors With Targeted Treatment

C. Ola Landgren, MD, PhD, on Managing a Complex Four-Agent Regimen in Myeloma

Luis G. Paz-Ares, MD, PhD, on Managing Immune-Related Adverse Events Associated With Checkpoint Inhibitor Therapy

Recent

CML AND COVID-19: Case Report of Successful Treatment With Tocilizumab

WCLC 2020: Adding Sintilimab to Chemotherapy for Nonsquamous NSCLC

DREAMM-4 Trial Update of Belantamab Mafodotin in Myeloma

KEYNOTE-629: Pembrolizumab in Metastatic Cutaneous Squamous Cell Carcinoma

Published

Medical Literature

Quality of Life During Pembrolizumab Treatment for Metastatic Triple-Negative Breast Cancer

Subcutaneous Versus Intravenous Pertuzumab/Trastuzumab in Early Breast Cancer: Patient Perspective

Novel Chimeric Monoclonal Antibody Under Study in Metastatic Colorectal Cancer

Novel Antibody-Drug Conjugate Under Study in Platinum-Sensitive Ovarian Cancer

Ongoing

Modest Responses With Immunotherapy Combo for Advanced Ovarian Cancer

Emerging Considerations in Triple-Negative Breast Cancer: Focus on Immunotherapy

BCOP Test-Advances in Targeted Therapy and Immunotherapy For The Treatment of Kidney Cancer

NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer

Available

Clinical Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

ClinicalTrials.gov Immunotherapy

Cancer Research Institute Immunotherapy Clinical Trials

Center for Immunotherapy Clinical Research Trials

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.